Ultragenyx touts Phase 3 win for gene therapy in rare glycogen storage disorder
Ultragenyx’s one-time gene therapy has hit the primary endpoint in a registrational test in a rare glycogen storage disorder, triggering company plans to file with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
